Clarithromycin versus metronidazole in first-line helicobacter pylori triple eradication therapy based on resistance to antimicrobial agents: Meta-analysis

Masaki Murata, Mitsushige Sugimoto, Hitomi Mizuno, Takeshi Kanno, Kiichi Satoh

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

Background: International treatment guidelines for Helicobacter pylori infection recommend a proton pump inhibitor (PPI)/amoxicillin/clarithromycin (CAM) regimen (PAC) or PPI/amoxicillin/metronidazole (MNZ) regimen (PAM) as first-line therapy based on culture and sensitivity testing. As incidence rates of antimicrobial agent-resistant strains are changing year by year, it is important to reevaluate the efficacy of eradication regimens. We performed a meta-analysis to evaluate the efficacy and safety of PAC and PAM based on different locations categorized by the reported incidence of CAM-and MNZ-resistant strains. Methods: Randomized control trials (RCTs) comparing eradication rates between PAC and PAM first-line treatment up to December 2018 were included. We divided RCTs into four groups based on resistance to CAM (< 15% or ≥ 15%) and MNZ (< 15% or ≥ 15%). Results: A total of 27 studies (4825 patients) were included. Overall eradication rates between PAC and PAM were similar (74.8% and 72.5%, relative risk (RR): 1.13, 95% confidence interval (CI): 0.91–1.39, P = 0.27) in the intention-to-treat analysis. In areas with low MNZ-and high CAM-resistance rates, PAM had a significantly higher eradication rate than PAC (92.5% vs. 70.8%, RR: 0.29, 95% CI: 0.13–0.68). In areas with high MNZ-and low CAM-resistance rates, the eradication rate with PAC was only 72.9%. Conclusions: Overall eradication rates with PAC and PAM were equivalent worldwide. In low MNZ-resistance areas, PAM may be recommended as first-line therapy. However, the efficacy of PAC may be insufficient, irrespective of susceptibility to CAM.

Original languageEnglish
Article number543
JournalJournal of Clinical Medicine
Volume9
Issue number2
DOIs
Publication statusPublished - 2020 Feb

Keywords

  • Clarithromycin
  • Eradication therapy
  • Helicobacter pylori
  • Metronidazole
  • Resistant
  • Triple therapy

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Clarithromycin versus metronidazole in first-line helicobacter pylori triple eradication therapy based on resistance to antimicrobial agents: Meta-analysis'. Together they form a unique fingerprint.

Cite this